Crinetics' CRN04777 Shows Dose-Dependent Suppression of Fasting Insulin

  • Crinetics Pharmaceuticals Inc CRNX announced topline results from the multiple ascending dose (MAD) cohorts of healthy volunteers in the Phase 1 study of CRN04777. 
  • CRN04777 is a nonpeptide somatostatin receptor type 5 (SST5) agonist as an oral treatment for congenital monogenic and syndromic hyperinsulinism. This condition causes individuals to have abnormally high insulin levels, which is a hormone that helps control blood sugar levels.
  • The data showed a rapid and sustained reduction of insulin secretion, including in a pharmacologic model of congenital hyperinsulinism (HI)
  • Consistent with the SAD findings, data from the MAD cohorts showed that CRN04777 inhibited insulin secretion and eliminated the need for glucose support in a model of hyperinsulinism. 
  • The new data are from 27 healthy volunteers who received once-daily oral doses of CRN04777 (30 mg, 60 mg, or 120 mg) or a placebo.
  • Pharmacokinetic and exposure profiles were consistent with expectations from the SAD cohorts, with CRN04777 being orally bioavailable with a half-life of approximately 40 hours. 
  • The Company held unrestricted cash, cash equivalents, and investments of $333.7 million.
  • JMP Securities analyst Jonathan Wolleben maintains Crinetics Pharmaceuticals with a Market Outperform and raises the price target from $43 to $45.
  • Price Action: CRNX shares are up 4.05% at $19.77 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsHealth CareSmall CapGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!